[
    "{\"step_by_step_thinking\": \"Document [1] states that lenacapavir is an investigational first-in-class agent that disrupts functioning of HIV capsid protein across multiple steps in the viral life cycle. It has demonstrated potent antiviral activity in persons with HIV-1. Document [6] mentions that lenacapavir received its first approval in the EU for use in combination with other antiretroviral(s) in adults with multi-drug resistant HIV infection. Document [8] also provides evidence from a phase 3 trial showing substantial antiviral activity of lenacapavir in patients with multidrug-resistant HIV-1 infection. Therefore, lenacapavir can be used for HIV.\", \"answer_choice\": \"A\"}"
]